Uso de la metformina en pacientes con el síndrome del ovario poliquístico

Autores/as

  • Donald Fernández Morales Caja Costarricense del Seguro Social, Hospital México
  • Felipe Sagot Verdesia Caja Costarricense del Seguro Social, Hospital México

DOI:

https://doi.org/10.51481/amc.v49i3.318

Palabras clave:

Metformina, síndrome del ovario poliquístico, hiperandrogenismo, hiperinsulinemia, resistencia a la insulina, acidosis láctica, oligoamenorreas, hirsutismo, inducción de ovulación

Resumen

La metformina es un medicamento indicado para el tratamiento de la diabetes mellitus tipo II con una función renal normal. Ha sido usada, sin la aprobación de la Administración de Drogas y Alimentos de los EEUU, en pacientes con el síndrome del ovario poliquístico, como regulador del trastorno menstrual, tratamiento del hirsutismo e inductor de ovulación.....

Citas

Kirpichnifov D, McFarlane S, Sowers J. Merformin: An Update. Ann Intern Med 2002; 137: 25–33

Burghen G, Givens J, Kitabchi A. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50:113-116

Dunaif A, Segal KR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in the polycystic ovary syndrome. Diabetes 1992; 41:1257-1266

Holte J, Bergh T, Berne C, Berglund L, Lithell H. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1994; 78: 1052-1058

Cibula D. Is insulin resistance an essential component of PCOS? Hum Reprod 2004; 19:757-759

Barbieri R. Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. Am J Obstet Gynecol 2000; 183:1414-1418

The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25

Alberti J, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062

Elkind-Hirsh K, Chang J. Use of insulin sensitizing agent in the treatment of polycystic ovary syndrome. American Society for Reproductive Medicine. Committee Opinion April 2000

Bailey C, Path M, Turner R. Metformin. N Engl J Med 1996; 334: 574-579

Moghetti P. Insulin resistance: what is its role in the polycystic ovary syndrome? Curr Opin Endocrinol Diabetes 2002; 9:444-450

Barbieri, R. Metformin for treatment of the polycystic ovary syndrome. UpToDate, Rose, BD(Ed), UpToDate, Wellesley, MA, 2004. Recuperado el 10 de enero del 2004 de http:// www.uptodate.com

Metformin: Drug Information. UpToDate, Rose, BD(Ed), UpToDate, Wellesley, MA, 2004. Recuperado el 10 de enero de 2004 de http:// www.uptodate.com

Misbin R, Stadel B. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338: 265 -266

Lalau JD, Race JM. Lactic Acidosis in Metformin Therapy. Drugs 1999; 58 Suppl.1: 55 – 60

Calabrese A, Coley K, DaPos S, Swanson D, Rao R. Risk of Lactic

Acidosis with Metformin Therapy. Arch Intern Med 2002; 162: 434–

Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003; 79: 1–13

Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003;361: 1894 - 1901

Kashyap S, Wells G, Rosenwaks Z. Insulin – sensitizing agents as primary therapy for patients with polycystic ovary syndrome. Hum Reprod 2004; 19: 2474-2483

Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dèchaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995; 80:2057–2062

Kolodziejczyk B, Duleba A, Spaczynski R, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73:1149–1154

Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002; 17: 1729-1737

Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4116–4123

Rosa Maciel G, Soares J, Alves E, Haidar M, Rodríguez E, Baracat E. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004; 81:355–360

Cibula D. Fanta M, Vrbikova J, Stanicka S, Dvorakova K, Hill M. The effect of combination therapy with metformin and combined oral contraceptives versus COC alone on insulin sensitivity, hiperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod 2004; 20:180–184

McCarthy E, Walker S, McLachlan K, Boyle J, Permezel M. Metformin in Obstetrics and Gynecologic Practice: a Review. Obstet Gynecol Survey 2004; 59: 118–127

Nestler J, Jakubowics J, Evans W, Pasquali R. Effects of metformin on spontaneous and clomiphene – induced ovulation en the polycystic ovary syndrome. N Engl J Med 1998; 338:1876–1780

Batukan C, Baysal B. Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome. Arch Gynecol Obstet 2001; 265: 124–127

Hung E, Ming N, Chung P. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 2001; 16:1625–1631

Vandermolen D, Ratts V, Evans W, Stovall D, Kauma S, Nestler J. Metformin increases de ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001; 75: 310–315

Sturrock N, Lannon B, Fay T. Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Clin Pharmacol 2002; 53:469–473

Heard M, Pierce A, Carson S, Buster J. Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril 2002; 77; 669–673

Nestler J, Stovall D, Akhter N, Iuorno M, Jakubowics D. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002; 77:209–215

Lord J, Wilkin T. Metformin in polycystic ovary syndrome. Curr Opin Obstet Gynecol 2004; 16: 481-486

National Collaborating Centre for Woman’s and Children Health. Fertility: assessment and treatment for people with fertility problems. Ovulation induction 2004. Recuperado el 1 de junio del 2005 de http://www.nice.org.uk/pdf/CG011fullguideline.pdf

Palomba S, Orio F, Falbo A, Manguso F, Russo T, Cascella T. Prospective parallel randomized double-blind double-dummy controlled clinical trial comparing climifene citrate and metformin as the first-line treatment for ovulation induction in non-obese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:4068 - 4074

Descargas

Publicado

2007-07-01

Cómo citar

Fernández Morales, D., & Sagot Verdesia, F. (2007). Uso de la metformina en pacientes con el síndrome del ovario poliquístico. Acta Médica Costarricense , 49(3), 140-146. https://doi.org/10.51481/amc.v49i3.318